Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

To be part of this study, you must have previously taken part in another research study for prostate cancer where you received at least one dose of the treatment called AAA617. You would also need to have completed all the requirements of that previous study, making you eligible for this follow-up.

Before joining, you'll need to sign a consent form, which means you understand and agree to take part. You must be an adult, aged between 18 and 100 years old, and this study is specifically for men, as it focuses on prostate cancer.

There are very few reasons why you might not be able to join. The main exclusion is if for any reason you wouldn't be able to complete the necessary health checks and examinations required by the study.

If you decide to join this study, you won't receive any new treatment for your prostate cancer. Instead, we'll be checking in with you every 6 to 8 months. During these visits, we will monitor certain health markers and conduct laboratory tests to see how you are doing over time. These visits are to look for any known or potential side effects of the AAA617 treatment you received in an earlier study.

The study aims to follow you for up to 10 years in total, starting from the very first dose of AAA617 you received in your original treatment study. The number of visits you'll need for this specific follow-up study will depend on how long it's been since your first AAA617 dose when you join. Some of the 10-year follow-up might have already been covered within your previous study. The total duration of the study depends on how many participants there are and how long their earlier treatment studies lasted.